



Rubix LS, Announces Close of Seed Investment Round

Funding will be used to scale combination device development and manufacturing in anticipation of projected FDA clearance for its orthopedic combination device

LAWRENCE, MASSACHUSETTS, USA, December 12, 2017 /EINPresswire.com/ -- Rubix LS, an emerging Biotech advisory, consultancy and medical device firm, today announces that it closed a seed investment round led by Massachusetts-based Healthcare IT and Life Sciences firm HERSS LLC.

Rubix LS will use the funding from this round to scale its combination device development and manufacturing in anticipation of the projected FDA clearance of its initial orthopedic combination device.

This investment taps into the company's momentum in 2017. It provides us the capital we need to maximize our business and marketplace opportunity. "We are proud to have the support of an investment firm like HERSS who shares our vision", said Reginald Swift, CEO of Rubix LS. "We've been steadily growing our revenue since our inception. This seed funding will be used to scale our combination device development, while at the same time, enabling us to propel our Biotech industry advisory and consultancy services worldwide."

The company is also announcing today that Eric Eagnet, CEO of HERSS, will be joining the Board of Advisors. "We are absolutely thrilled to have someone of Eric's caliber joining our Advisory Board," commented Swift. "Mr. Eagnet is a seasoned executive, business strategist, and entrepreneurial visionary. He brings a proven track record, strong business leadership, and incredible insights that will be of tremendous value to us. We're starting to see real momentum in the market, and having Eric part of our all-star team of advisors will create a great advantage for us."

About Rubix LS:

Rubix LS., was founded in 2016 to merge advanced technologies in the life-science arena to advance the therapy options for patients who are suffering from rare and orphan cancers and diseases. Rubix LS is developing combination devices, varied within different disciplines, that utilizes regenerative matrices developed from their nanotechnology methodology to combat ailments in multiple manners. Rubix LS is leveraging the nano-matrices and innovatively merging them into implantable devices that can intelligently target, destroy and grow cells for patients to combat highly resistant cancers that otherwise are difficult to treat from radiation and chemotherapy.

www.rubixls.com

About HERSS LLC:

HERSS is a Massachusetts-based firm that specializes in providing business enabling advisory, consulting, and seed funding solutions for Healthcare IT and [Life Science](#) companies. HERSS works with the most promising and innovative companies to help them navigate their way to the next stage of success.

Healthcare Resourcing and Seeding Solutions (HERSS).

www.herss.com

Stacy Arrazcaeta
Rubix LS
978-655-6770
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.